Brief: Tharimmune Announces Option Agreement For Key Technologies For Generating HER2/HER3 Antibody Drug Conjugates
23/04/2024 12:53
April 23 (Reuters) - Tharimmune Inc THAR.O :
* THARIMMUNE INC: ANNOUNCES OPTION AGREEMENT FOR KEY
TECHNOLOGIES
FOR GENERATING HER2/HER3 ANTIBODY DRUG CONJUGATES (ADCS)
* THARIMMUNE INC: OBTAINED RIGHTS FROM WASHINGTON UNIVERSITY
TO
DEVELOP AND INCORPORATE HUMAN HER2 DIRECTED ANTIBODIES
Source text for Eikon: ID:
Further company coverage: THAR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Canton Strategic Holdings
See all newsBrief: Canton Strategic Holdings, Inc. Expected To Be Included In Russell 3000® And Russell 2000®
Brief: Canton Strategic Authorizes Share Repurchase Program For Up To $50 Million In Common Stock
Canton Strategic Holdings Q1 net loss widens on higher expenses
Brief: Canton Strategic Holdings Reports Full Year 2025 Financial And Operational Results
Brief: Canton Strategic Holdings Inc - Enters Amended Sales Agreement With Clear Street And Virtu Americas - SEC Filing